4
Changes in Ownership
HALOZYME THERAPEUTICS, INC. Filed Acc 0001159036-26-000108
PRESIDENT AND CEO sold 60,000 shares at an average $104.59 ($6,275,592)
- PRESIDENT AND CEO acquired 60,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Torley Helen · PRESIDENT AND CEO
Table I: Non-derivative
14 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-08-17 | Exercise or conversion : show line 1 in the form 10b5-1 | +20,000 | $18.41 | $368,200 | 787,780 | D |
| 2026-08-17 | Sale : show line 2 in the form 10b5-1 | −900 | $98.96 | $89,062 | 786,880 | D |
| 2026-08-17 | Sale : show line 3 in the form 10b5-1 | −500 | $100.46 | $50,229 | 786,380 | D |
| 2026-08-17 | Sale : show line 4 in the form 10b5-1 | −2,100 | $101.77 | $213,709 | 784,280 | D |
| 2026-08-17 | Sale : show line 5 in the form 10b5-1 | −9,000 | $102.55 | $922,977 | 775,280 | D |
| 2026-08-17 | Sale : show line 6 in the form 10b5-1 | −7,500 | $103.48 | $776,115 | 767,780 | D |
| 2026-08-18 | Exercise or conversion : show line 7 in the form 10b5-1 | +20,000 | $18.41 | $368,200 | 787,780 | D |
| 2026-08-18 | Sale : show line 8 in the form 10b5-1 | −5,703 | $103.08 | $587,882 | 782,077 | D |
| Open-market sales · 60,000 sh · avg $104.59 · $6,275,592 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-08-17 | Exercise or conversion : show line 15 in the form 10b5-1 Option to Purchase Common Stock | −20,000 | $18.41 | $368,200 | 181,552 | D |
| 2026-08-18 | Exercise or conversion : show line 16 in the form 10b5-1 Option to Purchase Common Stock | −20,000 | $18.41 | $368,200 | 161,552 | D |
| 2026-08-19 | Exercise or conversion : show line 17 in the form 10b5-1 Option to Purchase Common Stock | −20,000 | $18.41 | $368,200 | 141,552 | D |
Loading xslF345X06/wk-form4_1787184072.xml…